• Q3 FY26 operating revenue of $5.4m, down 23.9% on prior corresponding period
• Q3 FY26 gross profit of $2.1m, down 36.7% on prior corresponding period
• Gross margin of 39.7%, down 8 ppts on prior corresponding period

Adheris Health Limited (ASX: AHE) provided its quarterly activities report and Appendix 4C for the three months ended 31 March 2026 (Q3 FY26). Q3 FY26 operating revenue was $5.4 million, down 23.9% on the prior corresponding period (Q3 FY25: $7.1 million), due to lower customer renewal rates in prior periods, lower bookings in 1H FY26 compared to prior year, and lower average deal sizes due to pharma budget pressures. Gross profit decreased to $2.1 million, down 36.7% on the prior corresponding period, reflecting the lower revenue, and gross margin decreased to 39.7%, down 8 percentage points on the prior corresponding period. The company continued to make progress on its five key short-term priorities, including building a more scalable operation, diversifying revenue, selling higher-margin solutions, expanding its network, and enhancing digital engagement. The company rolled out several feature enhancements and added improved functionality to its recently launched technology platform, which is expected to accelerate sales cycles, shorten time from contract to go-live, and lower cost to deliver. The company remains focused on achieving cashflow break-even in Q4 FY26.